Relacorilant is a small molecule commercialized by Corcept Therapeutics, with a leading Phase III program in Cushing’s Syndrome. According to Globaldata, it is involved in 23 clinical trials, of which 17 were completed, 5 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Relacorilants valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Relacorilant is expected to reach an annual total of $1.01 bn by 2034 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Relacorilant Overview
Relacorilant (CORT-125134) is under development for the treatment of endogenous Cushing's syndrome, advanced/metastatic solid tumors such as platinum-resistant ovarian cancer, adrenocortical carcinoma, triple negative breast cancer, fallopian tube cancer, primary peritoneal cancer, metastatic castration-resistant prostate cancer and pancreatic adenocarcinoma. It is a small molecule administered orally. The drug candidate is a next-generation cortisol modulator that targets glucocorticoid receptor II (GR-II). It was also under development for metastatic pancreatic ductal adenocarcinoma..
Corcept Therapeutics Overview
Corcept Therapeutics (Corcept) discovers, develops, and commercializes innovative medicines for the treatment of psychiatric, oncologic, and metabolic diseases. The companys marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome. Corcepts major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis, alcohol use disorder, and post-traumatic stress disorder among others. Corcept is headquartered in Menlo Park, California, the US.
The company reported revenues of (US Dollars) US$482.4 million for the fiscal year ended December 2023 (FY2023), an increase of 20% over FY2022. In FY2023, the companys operating margin was 22.2%, compared to an operating margin of 28% in FY2022. In FY2023, the company recorded a net margin of 22%, compared to a net margin of 25.2% in FY2022.
The company reported revenues of US$146.8 million for the first quarter ended March 2024, an increase of 8.4% over the previous quarter.
For a complete picture of Relacorilants valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
